Project leadersIgnasi Heras Vila and Carmen Peralta Uroz.
Participating organizationsIDIBAPS, Transplant Biomedicals
To develop a new device to conserve and transport organs to be transplanted (TB1) integrating conservation technology developed at the August Pi i Sunyer Biomedical Research Institute (IDIBAPS). The device aims to improve post-transplant and make the most of organs donated.
The TB1 project is the result of the relationship that brings together the science of excellence contributed by IDIBAPS, the spin-off created by the same institution and the development of a healthcare product by Transplant Biomedicals through to real use in hospitals. IDIBAPS and Transplant Biomedicals signed an exclusive licensing deal for the patent to TB1.
Most significant challenges
One of the initial challenges, during the pre-clinical validation of the technology, was to develop animal models as similar as possible to common clinical practice. After the pre-clinical validation, the greatest technological challenge was to scale up the technology to a clinical prototype adapted to human organs.
The most important challenge, however, has been to go from disruptive technology to a product that can be produced at an industrial scale, which is fully adapted to healthcare personnel and that international transplant centers will be interested in acquiring.
TB1 has currently completed pre-clinical validation for kidney and liver transplants. The results have shown the potential for reducing the injury organs experience in the ischemic phase between donor and receiver, an increase in post-transplant survival rates and the ability to take advantage of organs that are currently discarded.
The company has raised a cumulative €6.5 million in funding. They closed the first investment in 2017 for a medical device in Spain, with €2.5 million to complete development of the device and start a first-in-human clinical study in benchmark transplant hospitals in Catalonia in the second quarter of 2018: Hospital Clinic Barcelona, Hospital Bellvitge and Hospital Vall d'Hebron. The company expects to get CE marking by the end of 2018 and begin marketing the product in 2019.
In the future, Transplant Biomedicals hopes to diversify the technology and develop a TB1 to preserve livers and hearts for transplant over the next 2 years. To fund the next steps, they are considering series-B funding.